risedronic acid has been researched along with prednisone in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adami, S; Chines, AA; Devogelaer, JP; Reid, DM | 1 |
| Shiraki, M | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G | 1 |
| Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM | 1 |
| Reiss, S; Sultan, D | 1 |
2 review(s) available for risedronic acid and prednisone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; Humans; Osteitis Deformans; Osteoporosis; Prednisone; Risedronic Acid; Spinal Fractures | 2002 |
4 trial(s) available for risedronic acid and prednisone
| Article | Year |
|---|---|
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2001 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Menopause; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prednisone; Risedronic Acid; Sex Factors; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2013 |
6 other study(ies) available for risedronic acid and prednisone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Multicenter Studies as Topic; Netherlands; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risedronic Acid; Survival Analysis; Taxoids | 2013 |
Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis.
Topics: Abscess; Administration, Oral; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Female; Gingival Diseases; Glucocorticoids; Humans; Mandibular Diseases; Osteoporosis, Postmenopausal; Prednisone; Pulmonary Fibrosis; Risedronic Acid; Risk Factors | 2015 |